Le Lézard
Classified in: Health
Subject: PDT

Boston Heart Diagnostics Launches LipidSeqtm-- An NGS Test for Common Genetic Disorders of Lipid Metabolism


FRAMINGHAM, Mass. , Aug. 17, 2022 /PRNewswire/ -- Boston Heart Diagnostics, part of the Eurofins network of companies, announces the launch of LipidSeqtm, a revolutionary genetic test for cardiovascular disease. This saliva-based NGS test identifies the most common genetic causes of lipid and lipoprotein disorders. These disorders are associated with premature cardiovascular, pancreatic, kidney, and neurological diseases.

Boston Heart Diagnostics announces the launch of LipidSeqtm, a revolutionary genetic test for cardiovascular disease.

When patients have very high levels of low-density lipoprotein cholesterol, triglycerides, or plasma sterols and/or very low levels of high-density lipoprotein cholesterol, there is a likelihood of a genetic mutation. Conditions detected by this 23-gene test include familial forms of hypercholesterolemia, lysosomal acid lipase deficiency, sitosterolemia, cerebrotendinous xanthomatosis, dysbetalipoproteinemia, hypertriglyceridemia, and HDL deficiency states including ApoA-I deficiency, Tangier disease, and LCAT deficiency, as well as other disorders. If there is a genetic basis for the patient's condition, understanding the specific mutation and associated disease can help guide treatment considerations, educate the patient about health risks, and encourage relatives to seek testing to determine if they, too, may be at risk. Boston Heart is the only commercial laboratory able to test biochemical and genetic contributors when diagnosing inherited disorders of lipid metabolism (Reference: Schaefer EJ, Geller AS, Endress G. The biochemical and genetic diagnosis of lipid disorders. Current Opinion in Lipidology 2019; 30:56-62.)

Testing of appropriate patients can be done at any age, which favors early identification and treatment of genetically influenced lipid and lipoprotein disorders. Early diagnosis and precision treatment can save lives, and have a significant clinical impact for practitioners, patients, and their families.

LipidSeq was developed in collaboration with Eurofins laboratory partner Clinical Enterprise, which performs the genetic sequencing, and in consultation with Dr. Robert A. Hegele of Robarts Research Institute in London, Ontario.  

Healthcare providers may access this testing for their patients by signing up for an account with Boston Heart. The Boston Heart Customer Care department is available at 877.425.1252 or [email protected].

About Boston Heart Diagnostics Corporation

Boston Heart Diagnostics, a subsidiary of Eurofins Scientific (EUFI.PA), is transforming the treatment of cardiovascular disease and related conditions by providing healthcare providers and their patients with novel, personalized diagnostics and integrated customized lifestyle programs that have the power to change the way clinicians and patients communicate about disease and improve health. For more information on Boston Heart Diagnostics, please visit www.BostonHeartDiagnostics.com

SOURCE Boston Heart Diagnostics


These press releases may also interest you

at 16:20
Attorney Ilyas Sayeg, of mctlaw, has been appointed co-lead of the consolidated Exactech lawsuits in Florida's Eighth Judicial Circuit (Case No. 01-2022-CA-2670). These lawsuits involve patients dealing with the effects of Exactech's recalled hip,...

at 07:45
The Canadian Red Cross is encouraging people who are impacted by Hurricane Fiona to register with Red Cross by calling 1-800-863-6582, between the hours of 8 a.m. and 8 p.m. ADT or online at www.redcross.ca/hurricanefiona. Registration with the Red...

24 sep 2022
Well, the benefits from a boost in vitamins are widely known,...

24 sep 2022
The Canadian Red Cross has launched the Hurricane Fiona in Canada Appeal to support people across eastern Canada who have been impacted by this devastating hurricane. Money raised will enable the Red Cross to carry out relief, recovery, resiliency...

24 sep 2022
Trulieve Cannabis Corp.   ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, today announced the grand opening of its newest West Virginia dispensary in Milton at 5 Perry Morris Square. The Milton...

24 sep 2022
Trulieve Cannabis Corp.  ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, today announced the grand opening of its newest West Virginia dispensary in Belle at 2700 Dupont Ave Suite 9. The Belle...



News published on 17 august 2022 at 15:12 and distributed by: